Hatem Soliman, MD

Where You Are:

Hatem Soliman, MD

Medical Oncology

For Consultation Requests or Referrals: (888) 860-2778

 
 

BOARD CERTIFICATION:
          •  Hematology
          •  Medical Oncology

FELLOWSHIP:
          •  University of South Florida - Hematology/Oncology

RESIDENCY:
          •  University of South Florida - Internal Medicine

MEDICAL SCHOOL:
          •  Medical College of Georgia - MD

  • Soliman H, Saleh M, El-Matbouli M. Detection of Fish Pathogens by Loop-Mediated Isothermal Amplification (LAMP) Technique. Methods Mol Biol. 2015;1247:163-173. Pubmedid: 25399095.

  • Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget. 2014 Sep;5(18):8136-8146. Pubmedid: 25327557.

  • Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer version 3.2014. J Natl Compr Canc Ne. 2014 Apr;12(4):542-590. Pubmedid: 24717572.

  • Soliman H, Khalil F, Antonia S. PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells. PLoS One. 2014 FEB;9(2):e88557. Pubmedid: 24551119.

  • Luddy KA, Robertson-Tessi M, Tafreshi NK, Soliman H, Morse DL. The role of toll-like receptors in colorectal cancer progression: evidence for epithelial to leucocytic transition. Front Immunol. 2014;5:429. Pubmedid: 25368611. Pmcid: PMC4202790.

  • El-Kholy AA, Rady DI, Abdou ER, Elseafy MM, Abdelrahman KA, Soliman H. Construction, characterization and immunogenicity of a glycoprotein E negative bovine herpesvirus-1.1 Egyptian strain "Abu-Hammad". J Virol Methods. 2013 Dec;194(1-2):74-81. Pubmedid: 23962750.

  • Mediavilla-Varela M, Luddy K, Noyes D, Khalil FK, Neuger AM, Soliman H, Antonia S. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther. 2013 Aug;14(9). Pubmedid: 23917542.

  • Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2013 Jul;11(7):753-760. Pubmedid: 23847214. Pmcid: PMC3991132.

  • Soliman H, Rawal B, Fulp J, Lee JH, Lopez A, Bui MM, Khalil F, Antonia S, Yfantis HG, Lee DH, Dorsey TH, Ambs S. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol Immunother. 2013 Jun;62(5):829-837. Pubmedid: 23344392.

  • Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology. 2013 Mar;2(3):e23428. Pubmedid: 23802083.

  • Soliman H. Immunotherapy strategies in the treatment of breast cancer. Cancer Control. 2013 Jan;20(1):17-21. Pubmedid: 23302903.

  • Joh JE, Esposito NN, Kiluk JV, Laronga C, Khakpour N, Soliman H, Catherine Lee M. Pathologic Tumor Response of Invasive Lobular Carcinoma to Neo-adjuvant Chemotherapy. Breast J. 2012 Nov;18(6):569-574. Pubmedid: 23034096.

  • Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2012 Jul;10(7):821-829. Pubmedid: 22773798. Pmcid: PMC3753191.

  • Joh JE, Esposito NN, Kiluk JV, Laronga C, Lee MC, Loftus L, Soliman H, Boughey JC, Reynolds C, Lawton TJ, Acs PI, Gordan L, Acs G. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist. 2012 Jun;16(11):1520-1526. Pubmedid: 22016474. Pmcid: PMC3233285.

  • Soliman H. Developing an effective breast cancer vaccine. Cancer Control. 2010 Jul;17(3):183-190. Pubmedid: 20664516.

  • Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-991. Pubmedid: 20420527. Pmcid: PMC3146364.

  • Soliman H, Ferrari A, Thomas D. Sarcoma in the young adult population: an international view. Semin Oncol. 2009 Jun;36(3):227-236. Pubmedid: 19460580.

  • Soliman H, Agresta S. Current issues in adolescent and young adult cancer survivorship. Cancer Control. 2008 Jan;15(1):55-62. Pubmedid: 18094661.

  • Ling J, Pi W, Bollag R, Zeng S, Keskintepe M, Soliman H, Krantz S, Whitney B, Tuan D. The solitary long terminal repeats of ERV-9 endogenous retrovirus are conserved during primate evolution and possess enhancer activities in embryonic and hematopoietic cells. J Virol. 2002 Mar;76(5):2410-2423. Pubmedid: 11836419.

  • Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-dioxygenase: is it an immune suppressor?. Cancer J. 16(4):354-359. Pubmedid: 20693847. Pmcid: PMC3850167.

Dr. Hatem Soliman is a medical oncologist specializing in breast cancer in The Center for Women’s Oncology at Moffitt Cancer Center.  He treats women with all stages of breast cancer, from early disease to locally advanced, as well as metastatic breast cancers. 

Dr. Soliman is a member of the Experimental Therapeutics Program at Moffitt and participates in research on novel drug discoveries. His interest in cancer research dates back to his undergraduate studies in genetics at the University of Georgia, where he won the prestigious Howard Hughes Summer Research Grant.  While attending Medical College of Georgia, he was awarded a research fellowship grant and participated in a National Cancer Institute-sponsored study evaluating a new immune-stimulating vaccine for breast cancer.  Dr. Soliman continues to study vaccine therapies during his research activities at Moffitt.

Dr. Soliman has a strong interest in community service and volunteers at the Red Crescent Clinic in Tampa, providing primary health care services to people who are indigent or underinsured.  Dr. Soliman is fluent in Arabic.

TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions